Kuantum Papers Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 27, 2025, 12:43 pm

Quick Insight

Kuantum Papers Ltd, operating in the Paper & Paper Products industry, currently trades at a price of 113 with a market capitalization of ₹989 Cr. The stock's P/E ratio stands at 11.1, indicating potential undervaluation, supported by a ROE of 10.1% and ROCE of 11.4%. The company maintains a healthy operating profit margin of 18%, with Net Profit at ₹115 Cr. Notably, Kuantum Papers Ltd has strong reserves of ₹1,204 Cr and manageable borrowings of ₹654 Cr, reflected in a comfortable Interest Coverage Ratio of 7.90x. The firm's efficient working capital management is evident with a Cash Conversion Cycle of 107 days. Investors may find the stock attractive given the modest P/BV of 1.20x, suggesting room for growth.

Competitors of Kuantum Papers Ltd

All Competitor Stocks of Kuantum Papers Ltd

Quarterly Result

Last Updated: August 20, 2025, 7:55 am

Below is a detailed analysis of the quarterly data for Kuantum Papers Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 223.00 Cr.. The value appears to be declining and may need further review. It has decreased from 277.00 Cr. (Mar 2025) to 223.00 Cr., marking a decrease of 54.00 Cr..
• For Expenses, as of Jun 2025, the value is 183.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 217.00 Cr. (Mar 2025) to 183.00 Cr., marking a decrease of 34.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 20.00 Cr..
• For OPM %, as of Jun 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Mar 2025) to 18.00%, marking a decrease of 4.00%.
• For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Interest, as of Jun 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
• For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 36.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 20.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 28.00% (Mar 2025) to 26.00%, marking a decrease of 2.00%.
• For Net Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2025) to 12.00 Cr., marking a decrease of 14.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.38. The value appears to be declining and may need further review. It has decreased from 2.99 (Mar 2025) to 1.38, marking a decrease of 1.61.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 3:29 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: August 11, 2025, 2:14 pm

Below is a detailed analysis of the balance sheet data for Kuantum Papers Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 9.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,204.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,115.00 Cr. (Mar 2024) to 1,204.00 Cr., marking an increase of 89.00 Cr..
• For Borrowings, as of Mar 2025, the value is 654.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 512.00 Cr. (Mar 2024) to 654.00 Cr., marking an increase of 142.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 246.00 Cr.. The value appears to be improving (decreasing). It has decreased from 251.00 Cr. (Mar 2024) to 246.00 Cr., marking a decrease of 5.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,113.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,888.00 Cr. (Mar 2024) to 2,113.00 Cr., marking an increase of 225.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,619.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,475.00 Cr. (Mar 2024) to 1,619.00 Cr., marking an increase of 144.00 Cr..
• For CWIP, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 114.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 338.00 Cr.. The value appears to be declining and may need further review. It has decreased from 371.00 Cr. (Mar 2024) to 338.00 Cr., marking a decrease of 33.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,113.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,888.00 Cr. (Mar 2024) to 2,113.00 Cr., marking an increase of 225.00 Cr..

Notably, the Reserves (1,204.00 Cr.) exceed the Borrowings (654.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Kuantum Papers Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 21.07. This value is within the healthy range. It has increased from 15.60 (Mar 23) to 21.07, marking an increase of 5.47.
• For Diluted EPS (Rs.), as of Mar 24, the value is 21.07. This value is within the healthy range. It has increased from 15.60 (Mar 23) to 21.07, marking an increase of 5.47.
• For Cash EPS (Rs.), as of Mar 24, the value is 26.59. This value is within the healthy range. It has increased from 20.81 (Mar 23) to 26.59, marking an increase of 5.78.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 128.79. It has increased from 110.79 (Mar 23) to 128.79, marking an increase of 18.00.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 128.79. It has increased from 110.79 (Mar 23) to 128.79, marking an increase of 18.00.
• For Dividend / Share (Rs.), as of Mar 24, the value is 3.00. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 3.00, marking an increase of 3.00.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 138.81. It has decreased from 150.07 (Mar 23) to 138.81, marking a decrease of 11.26.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 38.81. This value is within the healthy range. It has decreased from 43.87 (Mar 23) to 38.81, marking a decrease of 5.06.
• For PBIT / Share (Rs.), as of Mar 24, the value is 33.28. This value is within the healthy range. It has decreased from 38.66 (Mar 23) to 33.28, marking a decrease of 5.38.
• For PBT / Share (Rs.), as of Mar 24, the value is 28.37. This value is within the healthy range. It has increased from 23.26 (Mar 23) to 28.37, marking an increase of 5.11.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 21.07. This value is within the healthy range. It has increased from 15.60 (Mar 23) to 21.07, marking an increase of 5.47.
• For PBDIT Margin (%), as of Mar 24, the value is 27.96. This value is within the healthy range. It has decreased from 29.23 (Mar 23) to 27.96, marking a decrease of 1.27.
• For PBIT Margin (%), as of Mar 24, the value is 23.97. This value exceeds the healthy maximum of 20. It has decreased from 25.76 (Mar 23) to 23.97, marking a decrease of 1.79.
• For PBT Margin (%), as of Mar 24, the value is 20.44. This value is within the healthy range. It has increased from 15.49 (Mar 23) to 20.44, marking an increase of 4.95.
• For Net Profit Margin (%), as of Mar 24, the value is 15.17. This value exceeds the healthy maximum of 10. It has increased from 10.39 (Mar 23) to 15.17, marking an increase of 4.78.
• For Return on Networth / Equity (%), as of Mar 24, the value is 16.35. This value is within the healthy range. It has increased from 14.08 (Mar 23) to 16.35, marking an increase of 2.27.
• For Return on Capital Employeed (%), as of Mar 24, the value is 18.31. This value is within the healthy range. It has decreased from 22.78 (Mar 23) to 18.31, marking a decrease of 4.47.
• For Return On Assets (%), as of Mar 24, the value is 9.73. This value is within the healthy range. It has increased from 8.05 (Mar 23) to 9.73, marking an increase of 1.68.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.27. This value is within the healthy range. It has decreased from 0.34 (Mar 23) to 0.27, marking a decrease of 0.07.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.45. This value is within the healthy range. It has decreased from 0.49 (Mar 23) to 0.45, marking a decrease of 0.04.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.67. It has decreased from 0.77 (Mar 23) to 0.67, marking a decrease of 0.10.
• For Current Ratio (X), as of Mar 24, the value is 1.02. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 23) which recorded 1.02.
• For Quick Ratio (X), as of Mar 24, the value is 0.64. This value is below the healthy minimum of 1. It has increased from 0.58 (Mar 23) to 0.64, marking an increase of 0.06.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 3.55. This value is below the healthy minimum of 4. It has decreased from 4.50 (Mar 23) to 3.55, marking a decrease of 0.95.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 14.24. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 23) to 14.24, marking an increase of 14.24.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 11.28. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 23) to 11.28, marking an increase of 11.28.
• For Earning Retention Ratio (%), as of Mar 24, the value is 85.76. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 85.76, marking an increase of 85.76.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 88.72. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 88.72, marking an increase of 88.72.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 7.90. This value is within the healthy range. It has increased from 5.39 (Mar 23) to 7.90, marking an increase of 2.51.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 5.29. This value is within the healthy range. It has increased from 3.81 (Mar 23) to 5.29, marking an increase of 1.48.
• For Enterprise Value (Cr.), as of Mar 24, the value is 1,786.29. It has increased from 1,555.37 (Mar 23) to 1,786.29, marking an increase of 230.92.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.47. This value is within the healthy range. It has increased from 1.19 (Mar 23) to 1.47, marking an increase of 0.28.
• For EV / EBITDA (X), as of Mar 24, the value is 5.27. This value is within the healthy range. It has increased from 4.06 (Mar 23) to 5.27, marking an increase of 1.21.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.12. This value is within the healthy range. It has increased from 0.80 (Mar 23) to 1.12, marking an increase of 0.32.
• For Retention Ratios (%), as of Mar 24, the value is 85.75. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 85.75, marking an increase of 85.75.
• For Price / BV (X), as of Mar 24, the value is 1.20. This value is within the healthy range. It has increased from 1.10 (Mar 23) to 1.20, marking an increase of 0.10.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.12. This value is within the healthy range. It has increased from 0.80 (Mar 23) to 1.12, marking an increase of 0.32.
• For EarningsYield, as of Mar 24, the value is 0.13. This value is below the healthy minimum of 5. It has increased from 0.12 (Mar 23) to 0.13, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness